Robert Yapundich, MD
Neurology · St George, UTNPI 1417996695
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,295 of the $106,589 with a category attached, or 85.7%. AbbVie accounts for 79.3% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2020 at $32,501 and has fallen 91.1% since, to $2,890 in 2024. Among neurology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $522.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Sunovion Pharmaceuticals Inc.$20K
- EMD Serono, Inc.$249
- Biogen$213
- UCB, Inc.$213
- Bristol Myers Squibb$187
- plus $858 from 23 others
Across 9 payments — averaging $5699.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$29K
- Novartis$18K
- Biogen$4K
What the payments were for
- Speaking & faculty fees$91,29586%
- Travel & lodging$11,93811%
- Food & beverage$3,2973%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $84,500 |
| Sunovion Pharmaceuticals Inc. | 41 | $20,368 |
| EMD Serono, Inc. | 6 | $249 |
| Biogen | 4 | $213 |
| UCB, Inc. | 4 | $213 |
| Bristol Myers Squibb | 5 | $187 |
| Novartis | 4 | $181 |
| Otsuka America Pharmaceutical, Inc. | 1 | $64 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| AstraZeneca(2 entities) | 2 | $44 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| MDD US Operations, LLC | 3 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $38 |
| Livanova USA, Inc. | 2 | $38 |
| SK Life Science, Inc. | 1 | $37 |
| Adamas Pharmaceuticals, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Genentech USA, Inc. | 1 | $27 |
| Pfizer | 1 | $25 |
| Banner Life Sciences, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Greenwich Biosciences, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Amgen | 1 | $12 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Nalu Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$106,589 in reported general payments places this provider in the 90th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 24 | $242,510 |
| NuplazidPimavanserin Tartrate | 14 | $200,547 |
| CopaxoneGlatiramer Acetate | 12 | $68,861 |
| Glatiramer Acetate | 13 | $34,944 |
| UbrelvyUbrogepant | 24 | $23,626 |
| Aimovig AutoinjectorErenumab-Aooe | 24 | $17,313 |
| GraliseGabapentin | 11 | $10,596 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,851 |
| Rivastigmine | 26 | $4,614 |
| Depakote ErDivalproex Sodium | 11 | $4,539 |
| Carbamazepine ErCarbamazepine | 42 | $2,944 |
| Lacosamide | 28 | $2,787 |
| Memantine Hcl | 98 | $2,772 |
| Levetiracetam | 91 | $2,759 |
| Levetiracetam ErLevetiracetam | 27 | $2,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $38 | $200,54714 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $41 | $68,86112 claims |
| AbbVieUbrelvy | $84,500 | $23,62624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 157 neurology providers in Utah.
Other neurology in St George
- Shawn AllenSt George$36K
- Trenton OverallSt George$8K
- Timothy WestSalt Lake City$856K
- Richard HammondOgden$707K
- Jeffrey GrovesDraper$628K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Yashma PatelLehi$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.